Theorem Clinical Research

R&D Trends

Rigel, Bristol-Myers Squibb ink R&D collaboration

Monday, February 23, 2015 01:01 PM

Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. T

More... »

Quest Diagnostics

Merck Serono, Sysmex Inostics open liquid biopsy RAS biomarker testing center

Friday, February 20, 2015 12:32 PM

Merck Serono, the biopharmaceutical business of Merck, has announced the opening of the first liquid biopsy RAS biomarker testing center in Vall d'Hebron's Institute of Oncology, Barcelona, Spain, and initially will test patients as part of its research program. This is an important milestone in making the new liquid biopsy RAS test available to patients with metastatic colorectal cancer (mCRC), and a significant step forward in Merck Serono's collaboration with Sysmex Inostics, a Germany-based molecular diagnostic company.

More... »


WHO urges governments to invest $34B for neglected tropical diseases

Friday, February 20, 2015 12:20 PM

The World Health Organization (WHO) has released a report urging countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low- and middle-income countries for the period 2015-2030.

More... »

NIH expands tuberculosis research program, awards $105.3M

Thursday, February 19, 2015 02:40 PM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is expanding its Tuberculosis Research Units (TBRU) program in an effort to drive innovation in tuberculosis (TB) research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.

More... »

Heat Biologics, OncoSec Medical collaborate on immunotherapy platforms

Thursday, February 19, 2015 02:38 PM

Heat Biologics, a clinical stage biopharmaceutical company developing cancer immunotherapies based in Durham, N.C., and OncoSec Medical, a San Diego, Calif.-based company developing DNA-based intratumoral cancer immunotherapies, have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.

More... »

Ferring Pharmaceuticals acquires BioSET orthobiologic product candidates

Thursday, February 19, 2015 02:37 PM

Ferring Pharmaceuticals, based in Saint Prex, Switzerland, has acquired the assets of Maryland-based BioSurface Engineering Technologies (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair. The initial indications for Amplex and Prefix to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. Both products are based on a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair.

More... »

Alzheimer's Research U.K. launches three Drug Discovery Institutes

Wednesday, February 18, 2015 11:57 AM

Alzheimer's Research U.K., a dedicated dementia research charity, has announced a $46.3 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of CambridgeOxford and University College London (UCL). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer's disease and other dementias.

More... »

Sanofi, Lead Pharma partner to develop treatments for autoimmune diseases

Wednesday, February 18, 2015 11:55 AM

Sanofi has entered into a research collaboration and license agreement with Dutch biotech Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common.

More... »

Angle, MD Anderson Cancer Center collaborate on colorectal cancer

Wednesday, February 18, 2015 11:49 AM

Angle, a specialist medtech company based in England, is collaborating with the MD Anderson Cancer Center to investigate the clinical use of Angle's Parsortix system as a companion diagnostic in colorectal cancer. The University of Texas MD Anderson Cancer Center is a center devoted exclusively to cancer patient care, research, education and prevention.

More... »

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015 11:45 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

More... »

AiCure
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs